CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Multiple CT scans may improve the accuracy of radiation therapy for prostate cancer.
PURPOSE: Phase I trial to study the effectiveness of multiple CT scans in guiding the treatment of patients who have prostate cancer and are undergoing radiation therapy.
|Prostate Cancer||Procedure: computed tomography Radiation: radiation therapy||Phase 2|
|Study Design:||Primary Purpose: Diagnostic|
|Official Title:||The Use Of Multiple CT Scans To Reduce Target Positioning Errors In Patients Undergoing External Beam Radiotherapy Treatment For Prostate Cancer|
- Treatment accuracy
- Reduction in the proportion of patients with large target positioning errors using CT guided procedure
- Organ motion and setup errors
|Study Start Date:||March 2001|
|Primary Completion Date:||June 2006 (Final data collection date for primary outcome measure)|
- Compare the accuracy of radiotherapy delivery using multiple CT scans to guide patient positioning vs the standard portal image guided procedure in patients with prostate cancer undergoing external beam radiotherapy.
- Determine the reduction in the proportion of patients with large target positioning errors using the CT-guided procedure.
- Determine organ motion and setup errors over the course of radiotherapy in order to develop efficient clinical intervention strategies in these patients.
OUTLINE: Patients undergo radiotherapy over 9 weeks. Patients undergo a CT scan immediately prior to receiving radiotherapy on treatment days 3-8 and then weekly thereafter. On 3 different days, patients also undergo CT scan immediately after radiotherapy. If the CT scans indicate a correction that exceeds the action level currently in effect, then beginning with the next treatment, the patient's position with respect to the radiation field is adjusted.
PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 2 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00020891
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||Michael Lovelock, PhD||Memorial Sloan Kettering Cancer Center|